---
layout: default
title: Antimony Trisulfide Iron Phosphorus Sulfur Theridi
parent: 僅模型預測 (L5)
nav_order: 334
evidence_level: L5
indication_count: 0
---

# Antimony Trisulfide Iron Phosphorus Sulfur Theridi
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Antimony Trisulfide / Thuja / Veratrum Compound: Homeopathic Multi-Ingredient Mixture — Evaluation Not Possible

## One-Sentence Summary

This candidate consists of a seven-component homeopathic mixture (Antimony Trisulfide, Iron, Phosphorus, Sulfur, Theridion Curassavicum, Thuja Occidentalis Leafy Twig, and Veratrum Album Root), none of which carry a known DrugBank identifier or recorded approved indication.
The TxGNN model returned **no predicted indications** for this combination, most likely because the compound lacks the standardised chemical identity required for knowledge-graph embedding.
Without a mechanistic anchor or regulatory history, a meaningful repurposing evaluation **cannot be completed at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no approved indication on record |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not applicable |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this compound. The model requires a DrugBank-mapped chemical entity with at least one known drug–disease or drug–protein edge in the knowledge graph. Because this product is an unlicensed homeopathic mixture of mineralogical and botanical materials — Antimony Trisulfide, elemental Iron, Phosphorus, Sulfur, the Caribbean spider *Theridion curassavicum*, *Thuja occidentalis* leafy twig, and *Veratrum album* root — none of the seven ingredients could be resolved to a DrugBank ID, and the combination as a whole has no knowledge-graph representation.

From a pharmacological standpoint, each component is used traditionally in homeopathic practice at highly diluted potencies. Conventional mechanism-of-action data (targets, pathways, binding affinities) are not established for these ingredients at the concentrations typically present in homeopathic preparations. Without a defined MOA, the graph-based and deep-learning prediction pipelines have no substrate to operate on.

A repurposing evaluation pathway designed for conventional small molecules or biologics is therefore not applicable here. Any future assessment would require either (a) identification of specific active components with documented pharmacology, or (b) a clinical evidence review conducted through a separate homeopathic/natural-product framework.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination or its individual homeopathic components under this compound identity.

---

## Literature Evidence

Currently no related literature available through the automated evidence collection pipeline for this compound. Relevant traditional-use or homeopathic literature, if any exists, would require a separate manual review outside the TxGNN evidence framework.

---

## Taiwan Market Information

This compound holds no Taiwan TFDA marketing authorisation. No license records were retrieved.

---

## Safety Considerations

Please refer to each individual component's package insert and relevant homeopathic regulatory guidance for safety information.

> **Note on Veratrum album**: *Veratrum album* root is pharmacologically active at conventional doses and carries significant toxicity risk (veratrum alkaloids cause bradycardia, hypotension, and neurotoxicity). If any preparation involves non-homeopathic concentrations of this plant, a full toxicological assessment is mandatory before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The compound has no DrugBank identity, no approved indication, no TxGNN repurposing prediction, and no safety data on file — the minimum data requirements for a Stage 1 repurposing assessment are not met.

**To proceed, the following is needed:**

- **Compound identity resolution**: Map each ingredient to a standardised identifier (DrugBank, ChEMBL, or PubChem CID) so knowledge-graph embedding becomes possible.
- **Active ingredient clarification**: Confirm whether this is a homeopathic dilution product or a botanical/mineral extract with pharmacologically active levels — the evaluation pathway differs substantially.
- **MOA documentation**: Retrieve mechanism-of-action data from DrugBank, ChEMBL, or primary literature for any ingredient that can be mapped.
- **Regulatory status clarification**: Determine the jurisdiction of origin and the regulatory category (homeopathic medicine vs. dietary supplement vs. prescription drug).
- **Toxicology review for Veratrum album**: If non-homeopathic concentrations are present, a formal safety assessment must precede any further evaluation.
- **Re-run TxGNN pipeline**: Once at least one ingredient is mapped to a DrugBank ID, re-submit individual components separately through the prediction pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

